Evogliptin tartrate has potential for anti-atherosclerosis therapy that targets arterial inflammation. Evogliptin tartrate is a potent, orally bioavailable and selective dipeptidyl peptidase-4 (DPP-4) inhibitor, with antidiabetic activity.
Talabostat isomer mesylate, an isomer of talabostat mesylate, is a potent, nonselective, and orally available inhibitor of dipeptidyl peptidase IV (DPP-IV) with a Ki of 0.18 nM. Talabostat (PT100, Val-boroPro) is notable for its efficacy in inhibiting DPP-IV.